From GlobeNewswire: 2024-05-26 14:00:00

The Global Precision Oncology Market is set to grow from USD 98.5 billion in 2023 to USD 260.5 billion by 2033, with a CAGR of 10.21%. Precision oncology uses genetics for targeted cancer treatment, reducing adverse effects. Advancements like AI-enabled radiological image analysis improve diagnosis accuracy, leading to better healthcare efficiency. Market growth is driven by increasing cancer prevalence and technological advancements.

The therapeutics segment dominates the global precision oncology market, offering customized treatments based on individual genetic profiles. Breast cancer is the most common cancer globally, leading the market in 2023. Hospitals play a crucial role in clinical trials and provide integrated precision oncology care. North America leads the market with extensive research activities, while the Asia-Pacific region is expected to grow rapidly due to awareness and healthcare development.

Key players in the Global Precision Oncology Market include Thermo Fisher Scientific Inc., Invitae Corporation, Illumina, Inc., and others. Recent developments include Thermo Fisher Scientific launching a next-generation sequencing test and analysis software for precise oncology biomarker testing. The market is segmented by product type, cancer type, end-user, and region for a comprehensive analysis and forecast from 2020 to 2033. Spherical Insights provides actionable market research and consulting services for decision-makers across various industries.



Read more at GlobeNewswire: Global Precision Oncology Market Size To Exceed USA 260.5